Results 61 to 70 of about 8,876 (157)
The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma
Cancer Medicine, 2018 Cytochrome P2C (CYP2C) subfamily members (CYP2C8, CYP2C9, CYP2C18, and CYP2C19) are known to participate in clinical drug metabolism. However, the association between CYP2C subfamily members and hepatocellular carcinoma (HCC) remains unclear.
Xiangkun Wang +11 more
doaj +1 more source
Exploration, Volume 6, Issue 1, February 2026.Circadian rhythm of epoxides and its diols in the kidney and plasma showed a significant light–dark manner. Furthermore, circadian disruption by timed‐imposed of EpSA from thermo‐induced oxidized oil during the inactive phase impaired renal function. ABSTRACT Modulation of circadian rhythms impairs homeostasis, resulting in altered susceptibility to ...
Yanjun Liu +6 more
wiley +1 more source
Characterization of the CYP2C8 Active Site by Homology Modeling
Chemical and Pharmaceutical Bulletin, 2004 To compare the features of the active sites of CYP2C8, CYP2C9, and CYP2C19, homology modeling was performed based on the crystallographic coordinates of mammalian CYP2C5. It was found that CYP2C8 has a much larger pocket than the other forms due to the existence of an additional pocket.
Toshimasa, Tanaka +3 more
openaire +3 more sources
Health Science Reports, Volume 9, Issue 2, February 2026.ABSTRACT Background and Aims The COVID‐19 pandemic has posed significant challenges for individuals with obstructive pulmonary diseases (OPDs), such as asthma and chronic obstructive pulmonary disease (COPD). Emerging evidence highlights the complex interplay between SARS‐CoV‐2 infection and OPDs, including increased risks of severe disease, long‐term ...
Behnam Dalfardi +6 more
wiley +1 more source
The Intersection of m6A Methylation and Immune Response in PCOS: A Bioinformatics Perspective
Immunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.N6‐methyladenosine RNA methylation regulators are intricately linked with the development of polycystic ovary syndrome (PCOS) and may influence immune cell infiltration in affected individuals. This study enhances our understanding of the molecular interactions in PCOS and suggests potential biomarkers for diagnosis and targets for therapeutic ...
Wenting Xu +8 more
wiley +1 more source
The Journal of Clinical Pharmacology, Volume 66, Issue 2, February 2026.Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene‐mutated metastatic castration‐resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe.
Mark Hadigol +5 more
wiley +1 more source
The Journal of Clinical Pharmacology, Volume 66, Issue 2, February 2026.Abstract Cytochrome P450 3A4 (CYP3A4) is an important drug‐metabolizing enzyme, whose function is impacted by age, sex, body weight, pregnancy, and disease. It is also the site of major drug interactions involving inhibition and induction. Because CYP3A4 is expressed in the intestine and liver, investigators have sought to study its function in both ...
David Rodrigues
wiley +1 more source
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype
Clinical Pharmacology & Therapeutics, 2006 Rosiglitazone is metabolically inactivated predominantly via the cytochrome P450 (CYP) enzyme CYP2C8. The functional impact of the CYP2C8*3 allele coding for the Arg139Lys and Lys399Arg amino acid substitutions is controversial. The purpose of this was to clarify the role of this polymorphism with regard to the pharmacokinetics and clinical effects of ...
Kirchheiner, Julia +11 more
openaire +3 more sources
Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants
Clinical and Translational Science, Volume 19, Issue 2, February 2026.ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Jason D. Kim +4 more
wiley +1 more source
Pharmacogenomics and Personalized Medicine, 2020 Lidia Habtemikael,1 Mulugeta Russom,2 Iyassu Bahta,2 Selam Mihreteab,3 Araia Berhane,4 Andreas Mårtensson,1 Jose Pedro Gil1,5,6 1Department of Women’s and Children’s Health, International Maternal and Child Health (IMCH), Uppsala ...
Habtemikael L +6 more
doaj